PI3K: from the bench to the clinic and back.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMC 2954281)

Published in Curr Top Microbiol Immunol on January 01, 2010

Authors

Bart Vanhaesebroeck1, Peter K Vogt, Christian Rommel

Author Affiliations

1: University of London, London, EC1M 6BQ, UK. bart.vanh@qmul.ac.uk

Articles citing this

Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21

Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods (2011) 2.56

Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67

Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes. PLoS One (2012) 1.30

Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol (2012) 0.98

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J (2012) 0.97

Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival. PLoS One (2012) 0.97

Classes of phosphoinositide 3-kinases at a glance. J Cell Sci (2014) 0.96

Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathog (2011) 0.96

Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther (2014) 0.93

Tripartite motif containing protein 27 negatively regulates CD4 T cells by ubiquitinating and inhibiting the class II PI3K-C2β. Proc Natl Acad Sci U S A (2011) 0.93

Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. FEBS Lett (2012) 0.89

Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One (2012) 0.88

Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic. EMBO J (2016) 0.87

Phosphoinositide 3-kinase p110δ promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization. Nat Commun (2015) 0.86

VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther (2012) 0.86

MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells. J Lipid Res (2013) 0.82

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia (2012) 0.79

Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease. PLoS One (2012) 0.77

Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. Sci Rep (2016) 0.75

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget (2016) 0.75

PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Sci Rep (2017) 0.75

PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A (2017) 0.75

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers (Basel) (2017) 0.75

Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep (2017) 0.75

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ. Nat Commun (2017) 0.75

Articles cited by this

(truncated to the top 100)

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36

Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36

Phosphoinositides in cell regulation and membrane dynamics. Nature (2006) 14.00

The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature (1997) 13.09

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 11.86

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61

Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58

Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47

Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science (1997) 8.17

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science (1993) 7.86

Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature (1999) 7.66

Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol (2008) 7.43

Role of translocation in the activation and function of protein kinase B. J Biol Chem (1997) 7.29

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A (2005) 7.21

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature (1985) 7.10

Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (1998) 6.79

Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci (2001) 6.66

Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56

A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science (1991) 6.54

Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46

A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature (1996) 6.32

The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28

Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26

PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01

Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature (1988) 5.88

Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell (1987) 5.87

Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science (2000) 5.84

Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev (1998) 5.77

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol (1997) 5.66

Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell (1991) 5.65

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J (1993) 5.53

EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. J Biol Chem (1995) 5.45

Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29

Characterization of VPS34, a gene required for vacuolar protein sorting and vacuole segregation in Saccharomyces cerevisiae. Mol Cell Biol (1990) 5.25

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem (2005) 5.22

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19

cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell (1991) 4.76

Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem (1990) 4.75

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71

Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A (1991) 4.66

The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol (2001) 4.64

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63

Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science (2000) 4.61

Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52

Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature (1994) 4.49

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30

Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (1995) 4.23

An 81 kd protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell (1987) 4.03

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02

PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96

Akt-dependent transformation: there is more to growth than just surviving. Oncogene (2005) 3.91

FYVE fingers bind PtdIns(3)P. Nature (1998) 3.91

Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science (1997) 3.91

Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem (1993) 3.88

Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci U S A (1984) 3.84

Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (1999) 3.81

P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell (2002) 3.80

The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J (1996) 3.78

Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71

Endosomal localization of the autoantigen EEA1 is mediated by a zinc-binding FYVE finger. J Biol Chem (1996) 3.53

A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell (1994) 3.50

Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science (1995) 3.40

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res (1994) 3.22

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19

Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem (1991) 3.17

Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15

Phox domain interaction with PtdIns(3)P targets the Vam7 t-SNARE to vacuole membranes. Nat Cell Biol (2001) 3.14

P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09

Pleckstrin domain homology. Nature (1993) 3.03

The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell (1997) 3.03

A putative modular domain present in diverse signaling proteins. Cell (1993) 2.90

High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem (1997) 2.88

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77

Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J (1998) 2.75

Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nat Genet (2009) 2.72

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol (2002) 2.70

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med (2002) 2.68

Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol (2003) 2.63

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62

Articles by these authors

(truncated to the top 100)

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62

Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05

The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med (2005) 5.05

Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26

Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15

The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15

PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12

Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov (2007) 2.97

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91

Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70

Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45

Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35

Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol (2006) 2.29

PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med (2005) 2.28

Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 2.19

Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11

Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood (2005) 2.05

PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov (2006) 1.85

Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72

Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68

Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67

Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res (2012) 1.65

Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res (2005) 1.59

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55

PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov (2011) 1.54

Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem (2006) 1.54

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol (2013) 1.47

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther (2011) 1.41

Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 1.36

Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol (2008) 1.31

Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood (2007) 1.27

100 years of Rous sarcoma virus. J Exp Med (2011) 1.24

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22

Involvement of phosphoinositide 3-kinase gamma, Rac, and PAK signaling in chemokine-induced macrophage migration. J Biol Chem (2004) 1.20

Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation (2008) 1.20

A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20

Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol (2005) 1.20

Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17

Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16

Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene (2003) 1.16

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood (2012) 1.14

Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle (2010) 1.11

Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11

Defining the role of TORC1/2 in multiple myeloma. Blood (2011) 1.10

Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A (2003) 1.09

Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med (2007) 1.09

Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thromb Haemost (2006) 1.09

PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol (2012) 1.07

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat (2012) 1.07

Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits. Mol Cell Biol (2009) 1.05

Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des (2004) 1.05

Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A (2004) 1.01

Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc Natl Acad Sci U S A (2012) 1.00

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood (2007) 1.00

Strategies for chemokine antagonists as therapeutics. Semin Immunol (2003) 0.98

Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98

Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol (2009) 0.98

Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J Immunol (2007) 0.96

MafA has strong cell transforming ability but is a weak transactivator. Oncogene (2003) 0.96

Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene (2003) 0.96

Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep (2008) 0.95

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem (2012) 0.94

An essential role for protein synthesis in oncogenic cellular transformation. Oncogene (2004) 0.94

Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene (2002) 0.94

Chemical inducers and transcriptional markers of oligodendrocyte differentiation. J Neurosci Res (2010) 0.94

Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93

Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. J Am Chem Soc (2009) 0.93

Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. J Am Chem Soc (2011) 0.93

Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther (2007) 0.93

The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 0.92

Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol Pharmacol (2009) 0.90

Functional whole-genome analysis identifies Polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin. J Biol Chem (2009) 0.89

Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget (2010) 0.88

Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. J Am Chem Soc (2004) 0.88

MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J Biol Chem (2004) 0.88

Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J Biol Chem (2007) 0.88

A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages. Mol Cell Proteomics (2007) 0.88

An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Mol Ther Nucleic Acids (2013) 0.87

A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87

Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer (2009) 0.87

Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res (2009) 0.86

Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer (2010) 0.84

Chemokine receptor CCR2 undergoes transportin1-dependent nuclear translocation. Proteomics (2008) 0.83

Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle (2011) 0.83

The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry (2005) 0.83

PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood (2008) 0.82

Progress in breast cancer research. Proc Natl Acad Sci U S A (2012) 0.82

Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle (2011) 0.81

Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods Enzymol (2008) 0.81

Cell entry by non-enveloped viruses. Curr Top Microbiol Immunol (2010) 0.81

The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene (2003) 0.80

Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene (2003) 0.80

MYCNOS functions as an antisense RNA regulating MYCN. RNA Biol (2015) 0.79

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. J Biol Chem (2009) 0.78

v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77